OUTbio Board Members
Ramsey Johnson is the founder and President of OUTbio. In his “day job”, Ramsey is a clinical and regulatory operation professional with over 24 years of experience with special expertise in rare genetic disorders. He is currently the VP, Operations for Phoenix Tissue Repair and was previously the Sr. Director of Clinical Operations for X4 Pharmaceuticals. Prior to X4, Ramsey was the Sr. Director of Clinical and Regulatory Operations for Edimer Pharmaceuticals. In 2015, Ramsey founded OUTbio with a desire to create a community where LGBTQ professionals in drug development could network and feel supported in their industry.
Tom is a senior biotech communications consultant, with both in-house and agency experience assisting a wide variety of global clients. Tom was formerly a Vice President at premier biotech consultancy Ten Bridge Communications, based in Boston, Massachusetts. Prior to that, he served as Director of Communications at NASDAQ-listed drug developer Nexvet Biopharma. Originally hailing from Hong Kong and New Zealand, Tom holds a master's degree in biotech business (first class honours), and a bachelor's degree in biomedical science. Tom is the Secretary of OUTbio.
CJ Hameed is a biomedical informatician with diverse experience in healthcare, spanning from patient care, academia, clinical research and informatics. He currently works at Pfizer, and in his earlier work, led the Informatics initiative at Neuroscience RU and, later, steered the development of interoperable drug discovery & analytics platforms for real world and clinical trial studies. He also held several academic positions and currently teaches at Northeastern University. CJ holds a master's degree in health informatics from Northeastern University and a medical degree from Dow University of Health Sciences. He is a Health Information Management System Society & American Medical Informatics Association (AMIA) fellow.
Bryan Hoffman is the Treasurer and Board member for OUTbio. Bryan is married to his husband, Josh, and has a 4 year old son, 3 dogs, and a turtle. He is also the founder and CEO of Boston Microscopes, a company specializing in the sales and service of microscopes, cameras and imagers. Bryan enjoys skiing, swimming, tennis, and outdoor activities. Being an advocate for the LGBT+ community is an important part of his life. Bryan holds a bachelor's degree in animal sciences from Cornell University.
Patrick is a high-performing scientist, independent thinker, recognized innovator, effective communicator, and respected colleague with over 20 years of experience in oncology research. He currently works as a researcher at Takeda Oncology. Outside of oncology drug discovery research, Patrick is passionate about giving back to the LGBTQ community. Patrick is a veteran rider/swimmer of the Harbor 2 the Bay (H2B) and the Provincetown Swim for Life, charters that both raise money for LGBTQ causes. He holds a bachelor's degree in biology from Bates College.
Patrick McNamara is Vice President and Head of Clinical Operations at Blueprint Medicines where he leads the clinical trial operations for their development programs focused on precision oncology medicines. Prior to Blueprint, Patrick was a Director of Clinical Operations at Takeda/Millennium Pharmaceuticals and previously managed clinical trials at Wyeth (formerly Genetics Institute). Prior to his roles in drug development, Patrick was a genetic counselor at Massachusetts General Hospital. He has a master’s degree in genetic counseling from the University of Pittsburgh and a bachelor’s degree in biology from Pennsylvania State University.
Dr. Petter is the founding CEO and current CSO of Arrakis Therapeutics. Previously, Jennifer was Vice President of Drug Discovery at Avila Therapeutics and, upon the acquisition of Avila by Celgene in 2012, she became Celgene’s Vice President of Chemistry, a position she held until leaving to found Arrakis in 2015. Prior to Avila, Jennifer served as Vice President of Research at Mersana Therapeutics, Director of Small Molecule Drug Discovery at Biogen and as Section Head in Oncology Chemistry at Sandoz/Novartis. Prior to her career in industry, Jennifer was an Assistant Professor of Chemistry at the University of Pittsburgh. Jennifer holds an A.B. in chemistry from Dartmouth College and earned her PhD in organic chemistry at Duke University with Ned Porter. She was a post-doctoral fellow in Ron Breslow’s group at Columbia University.
Abby Polkinghorn is a biotechnical recruiter and currently works at bluebird bio, a gene therapy company focusing on oncology and severe genetic diseases. Abby has a diverse medical and biotechnical recruiting background, with a primary concentration on Quality and Manufacturing businesses. Since 2019 Abby has independently led bluebird bio’s LGBTQ+ employee resource group, which currently has over 200 members. She takes great pride in helping those she works with feel accepted, understood, and safe. Abby holds a bachelor’s degree in marketing from Simmons College.
Joe is a senior program manager at Alnylam, where he leads early stage cross-functional program teams. He has a specific background in clinical development, with over 10 years of experience in all phases of drug development (from CTA-enabling through post-approval) in a variety of indications , including rare disease, hematology, CNS, CV. He is energized by helping teams form and evolve. Joe holds a bachelor's degree in psychology from Syracuse University and an MBA from UMass, Amherst.
Susu is the CEO and Founder of Tomo360, an online marketing agency since 2012. She leads an experienced business and marketing team that works on a variety of companies from high-tech industry, healthcare, biotech, higher education to startup companies. Susu is an advocate in helping women advancing their careers. She is the Co-Founder of Women Accelerators, a grassroots organization that provides networking, education, and mentoring to help women in advancing their career goals. She holds an MBA from Lesley University.